Why Viking Therapeutics Stock Zoomed 5% Higher Today

Viking Therapeutics (NASDAQ: VKTX) shares gained over 5% following a sympathy rally triggered by Novo Nordisk's FDA approval of Wegovy for a new MASH indication, boosting sentiment across the obesity drug sector. This positive momentum was reinforced by Piper Sandler analyst Biren Amin, who reiterated an 'overweight' rating and a $71 price target for VKTX, citing strong prospects for its oral weight-loss drug VK2735, which has a Phase 3 readout expected this quarter and an estimated sales potential of $2.1 billion.

Analysis

Viking Therapeutics (VKTX) stock demonstrated significant strength, climbing over 5% while the broader S&P 500 index remained flat. This outperformance was driven by two distinct positive catalysts. Firstly, the stock benefited from a sympathy rally following competitor Novo Nordisk's announcement that its drug, Wegovy, received FDA approval for a new indication in treating the liver disorder MASH. This regulatory success broadens the perceived therapeutic and commercial potential for the entire class of obesity drugs, boosting investor sentiment for companies with similar assets. Secondly, this momentum was reinforced by a bullish research note from Piper Sandler analyst Biren Amin, who reiterated an "overweight" rating and a $71 per-share price target. Amin's thesis is predicated on the potential of Viking's own investigational drug, VK2735, particularly its oral version, which is expecting a Phase 3 data readout within the current calendar quarter. The analyst projects that a successful market entry for oral VK2735 could generate sales of $2.1 billion, highlighting a substantial, company-specific growth driver independent of the sector-wide news.

Key Decisions for Investors

• Investors should monitor the upcoming Phase 3 clinical trial data for the oral version of VK2735, expected this quarter, as it represents a significant, near-term binary catalyst for the stock.
• Consider the broader market implications of Novo Nordisk's expanded FDA approval for Wegovy, as it suggests a larger total addressable market for GLP-1 agonists beyond weight loss, which could provide a long-term tailwind for Viking.
• Evaluate the $71 price target and $2.1 billion sales projection from Piper Sandler as a specific valuation framework, weighing this potential upside against the inherent clinical and regulatory risks of a biotech firm awaiting pivotal trial results.